Klinik für Strahlenheilkunde, Charité Centrum 6 für Diagnostische und Interventionelle Radiologie und Nuklearmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Clin Nucl Med. 2009 Dec;34(12):869-73. doi: 10.1097/RLU.0b013e3181becfcb.
Somatostatin receptor scintigraphy (SRS) is an established imaging modality for neuroendocrine tumors (NET). Additional single photon emission computed tomography (SPECT-CT) not only permits image fusion but also attenuation correction (AC) of SPECT data. This study evaluated whether attenuation corrected SPECT-images (SPECT[AC]) are more sensitive than nonattenuation corrected SPECT-reconstructions (SPECT[NAC]) for the detection of NET lesions.
The imaging data (planar In-111-octreotide scintigraphy and SPECT-CT) of 50 consecutive patients (28 male; 22 female; age, 34-80; mean, 65 years) with NET were included in this retrospective analysis. SPECT data were reconstructed with and without integrated CT-based AC and then analyzed by 2 experienced readers for the presence of pathologic uptake in a blinded consensus reading. Fused SPECT-CT, contemporary CT/MRI, and clinical as well as imaging follow-up served as a reference standard. All foci were rated in both the SPECT(NAC)- and SPECT(AC)-reconstructions for intensity and contrast using a 6-point-score ("0 = no uptake/no delineation from surrounding tissue" to "5 = very high uptake/very strong delineation from surrounding tissue"). The scores were analyzed in a 6 x 6 contingency table using the McNemar Bowker test.
A total of 222 pathologic foci were detected by SPECT(NAC) and 227 foci by SPECT(AC), respectively. In 67 of 227 foci (29.5%), focus intensity/contrast increased after AC, whereas only 5 foci showed a decrease (P < 0.001). Sensitivity increased by 2.2% (P = 0.025; 95% CI: 0.02%-4.1%) as 5 foci were detected only by SPECT(AC). However, as these 3 patients were already diagnosed with systemic disease, there was no influence on the therapeutic strategy chosen.
Attenuation correction of somatostatin receptor scintigraphy-SPECT significantly improves focus visualization and, albeit slightly, also significantly increases sensitivity.
生长抑素受体闪烁显像(SRS)是神经内分泌肿瘤(NET)的一种成熟的影像学方法。附加的单光子发射计算机断层扫描(SPECT-CT)不仅允许图像融合,还允许 SPECT 数据的衰减校正(AC)。本研究评估了衰减校正的 SPECT 图像(SPECT[AC])是否比未衰减校正的 SPECT 重建(SPECT[NAC])更敏感地检测 NET 病变。
本回顾性分析纳入了 50 例连续 NET 患者(28 名男性;22 名女性;年龄 34-80 岁;平均年龄 65 岁)的成像数据(In-111-奥曲肽闪烁显像和 SPECT-CT)。SPECT 数据分别在有和没有集成 CT 基 AC 的情况下进行重建,然后由 2 名有经验的读者进行盲法共识阅读,以分析病理性摄取的存在。融合的 SPECT-CT、当代 CT/MRI 以及临床和影像学随访均作为参考标准。所有焦点均在 SPECT[NAC]和 SPECT[AC]重建中使用 6 分评分(“0 = 无摄取/无与周围组织的边界”至“5 = 非常高摄取/非常强与周围组织的边界”)进行强度和对比度评分。使用 Mcnemar-Bowker 检验对 6x6 列联表中的评分进行分析。
SPECT[NAC]检测到 222 个病理性焦点,SPECT[AC]检测到 227 个焦点。在 227 个焦点中的 67 个(29.5%),焦点强度/对比度在 AC 后增加,而只有 5 个焦点减少(P < 0.001)。灵敏度提高了 2.2%(P = 0.025;95%CI:0.02%-4.1%),因为 SPECT[AC]仅检测到 5 个焦点。然而,由于这 3 名患者已被诊断为全身性疾病,因此对所选治疗策略没有影响。
生长抑素受体闪烁显像 SPECT 的衰减校正显著改善了焦点可视化,并且尽管略有改善,也显著提高了灵敏度。